This NDC is on FDA's drug shortage list (posted Jul 14, 2023)

Product Information

VYVANSE 20 MG CAPSULE is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $12.3430 per EA under NDC 59417010210. Its NADAC has been published 678 times since Nov 28, 2013.

FDA first approved this application on Feb 23, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the lisdexamfetamine dimesylate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

VYVANSE 20 MG CAPSULE

lisdexamfetamine dimesylate
$12.3430per EA
High Outlier
DEA Schedule CII

Strength

20 mg/1

NDC

59417010210

Classification

Brand

Dosage Form

CAPSULE

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

LISDEXAMFETAMINE DIMESYLATE

Approval Type

New Drug (NDA)

FDA Application

NDA021977

FDA Approved

2/23/2007

TE Code

AB

On Market Since

12/10/2007

Pharmacological Classes

Central Nervous System Stimulant
Central Nervous System Stimulation

Price Statistics

The NADAC for VYVANSE 20 MG CAPSULE has been published 678 times since Nov 28, 2013, and over the history we have for it it has risen 105.4%. The table below summarizes its recorded NADAC range and movement.

Current price$12.3430 per EA
All-time high$12.3947 (Sep 11, 2024)
All-time low$6.0083 (Nov 28, 2013)
52-week high$12.3586
52-week low$12.3430
Median price$10.2120
Average price$9.9773
Largest weekly change+9.0% (Jan 8, 2014)
Weeks tracked678
Tracking sinceNov 28, 2013

Price History

1W

-0.0%

1M

-0.0%

3M

-0.0%

6M

-0.1%

1Y

-0.1%

3Y

+4.6%

5Y

+15.3%

All

+105.4%

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 79% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of VYVANSE 20 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for VYVANSE 20 MG CAPSULE, manufactured by Takeda Pharmaceuticals America, Inc., is $12.3430 per EA (NDC 59417010210), effective Nov 18, 2026.

How has the price of VYVANSE 20 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for VYVANSE 20 MG CAPSULE has risen 105.4%. It has been tracked across 678 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for VYVANSE 20 MG CAPSULE?

Since Nov 28, 2013, the NADAC for VYVANSE 20 MG CAPSULE has ranged from a low of $6.0083 (Nov 28, 2013) to a high of $12.3947 (Sep 11, 2024), with a median of $10.2120 per EA.

Are there cheaper alternatives to VYVANSE 20 MG CAPSULE?

Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LISDEXAMFETAMINE 20 MG CAPSULE, is $2.6012 per EA — about 79% below VYVANSE 20 MG CAPSULE.

Who manufactures VYVANSE 20 MG CAPSULE?

VYVANSE 20 MG CAPSULE (NDC 59417010210) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.

Is VYVANSE 20 MG CAPSULE in shortage?

Yes — NDC 59417010210 is currently listed in FDA's drug shortage database (posted Jul 14, 2023).